About this trial
The purpose of the study is to identify patients who respond to treatment.
Unfortunately there is no readily available clinical test, at present, which accurately differentiates responders from non-responders, thus a number of women are prescribed treatment with potentially severe toxicity without knowing whether they will benefit from it.
If you take part in this study an extra sample of blood will be taken at up to 8 time points during and after your treatment regimen. You will be having routine bloods taken at these time points so we will just take an extra sample at those times.
During biopsy and surgery, if possible, we would like to send a very small sample from your tumour to the research laboratory for molecular profiling in order to correlate molecular expression profiles from the tumour (University Hospital Galway only) and blood.
All newly diagnosed breast cancer patients who are scheduled to undergo neoadjuvant chemotherapy will be recruited and enrolled into this study at the time of diagnosis, pending gaining informed consent.
Recurrent breast cancer patients
All patients with a history of breast cancer who represent with disease recurrence or progression, and are commencing up-front hormonal therapy or chemotherapy, will also be recruited and enrolled.
If you take part in this study an extra sample of blood will be taken at 5 time points during and after your treatment regimen. You will be having routine bloods taken at these time points so we will just take an extra sample at those times.
Where’s this trial being run?Beaumont Hospital, Bon Secours Cork, Midland Regional Hospital Tullamore, Our Lady of Lourdes Hospital, Drogheda, Sligo University Hospital, St James’s Hospital, St Vincents University Hospital, University Hospital Galway, and University Hospital Waterford
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
Circulating miRNAs: Novel breast cancer biomarkers and their use for guiding and monitoring response to therapy.
|Principal Investigator:||Prof Michael Kerin (University Hospital Galway)|
Cancer Trials Ireland
Global: Not Applicable
Ireland: May 2011
|Global Recruitment Target:||Not Applicable|
|Ireland Recruitment Target:||366|